Effect of hepatic drug transporter polymorphisms on the pharmacokinetics of mycophenolic acid in patients with severe renal dysfunction before renal transplantation

References

• Bowalgaha K, Miners JO. (2001). The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol 52:605–9.
   PubMed Web of Science ®Google Scholar
• Bullingham RE, Nicholls AJ, Kamm BR. (1998). Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34:429–55.
   PubMed Web of Science ®Google Scholar
• Colom H, Lloberas N, Andreu F, et al. (2014). Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. Kidney Int 85:1434–43.
   PubMed Web of Science ®Google Scholar
• Cox VC, Ensom MH. (2003). Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit 25:137–57.
   PubMed Web of Science ®Google Scholar
• Fujiyama N, Miura M, Kato S, et al. (2010). Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil. Drug Metab Dispos 38:2210–17.
   PubMed Web of Science ®Google Scholar
• Gill KL, Houston JB, Galetin A. (2012). Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. Drug Metab Dispos 40:825–35.
   PubMed Web of Science ®Google Scholar
• Inoue K, Miura M, Satoh S, et al. (2007). Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Ther Drug Monit 29:299–304.
   PubMed Web of Science ®Google Scholar
• Kagaya H, Inoue K, Miura M, et al. (2006). Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. Yakugaku Zasshi 126:1357–62.
   PubMed Web of Science ®Google Scholar
• Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y. (2005). The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 78:351–61.
   PubMed Web of Science ®Google Scholar
• Matsunaga N, Wada S, Nakanishi T, et al. (2014). Mathematical modeling of the in vitro hepatic disposition of mycophenolic acid and its glucuronide in sandwich-cultured human hepatocytes. Mol Pharm 11:568–79.
   PubMed Web of Science ®Google Scholar
• Miura M, Kagaya H, Satoh S, et al. (2008). Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit 30:559–64.
   PubMed Web of Science ®Google Scholar
• Miura M, Satoh S, Inoue K, et al. (2007). Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 63:1161–9.
   PubMed Web of Science ®Google Scholar
• Miura M, Satoh S, Niioka T, et al. (2009). Early phase limited sampling strategy characterizing tacrolimus and mycophenolic acid pharmacokinetics adapted to the maintenance phase of renal transplant patients. Ther Drug Monit 31:467–74.
   PubMed Web of Science ®Google Scholar
• Mukai M, Tanaka S, Yamamoto K, et al. (2014). In vitro glucuronidation of propofol in microsomal fractions from human liver, intestine and kidney: tissue distribution and physiological role of UGT1A9. Pharmazie 69:829–32.
   PubMed Web of Science ®Google Scholar
• Müller PJ, Dally H, Klappenecker CN, et al. (2009). Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients. Int J Cancer 124:1669–74.
   PubMed Web of Science ®Google Scholar
• Naesens M, de Loor H, Vanrenterghem Y, Kuypers DR. (2007). The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. Transplantation 84:362–73.
   PubMed Web of Science ®Google Scholar
• Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. (2006). Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 82:1074–84.
   PubMed Web of Science ®Google Scholar
• Nozawa T, Nakajima M, Tamai I, et al. (2002). Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 302:804–13.
   PubMed Web of Science ®Google Scholar
• Ohno S, Nakajin S. (2009). Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32–40.
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Conti D, Dunn J, et al. (2000). Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clin Transplant 14:179–88.
   PubMed Web of Science ®Google Scholar
• Picard N, Yee SW, Woillard JB, et al. (2010). The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharmacol Ther 87:100–8.
   PubMed Web of Science ®Google Scholar
• Roth D, Colona J, Burke GW, et al. (1998). Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. Transplantation 27:248–52.
   Google Scholar
• Sasaki T, Hirota T, Ryokai Y, et al. (2011). Systematic screening of human ABCC3 polymorphisms and their effects on MRP3 expression and function. Drug Metab Pharmacokinet 26:374–86.
   PubMed Web of Science ®Google Scholar
• Shaw LM, Holt DW, Oellerich M, et al. (2001). Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 23:305–15.
   PubMed Web of Science ®Google Scholar
• Shipkova M, Strassburg CP, Braun F, et al. (2001). Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol 132:1027–34.
   PubMed Web of Science ®Google Scholar
• Squifflet JP, Backman L, Claesson K, European Tacrolimus-MMF Renal Study Group, et al. (2001). Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 15:63–9.
   Web of Science ®Google Scholar
• Staatz CE, Tett SE. (2007). Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 46:13–58.
   PubMed Web of Science ®Google Scholar
• Tsujimoto M, Hirata S, Dan Y, et al. (2006). Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects. Drug Metab Pharmacokinet 21:165–9.
   PubMed Web of Science ®Google Scholar
• Uwai Y, Motohashi H, Tsuji Y, et al. (2007). Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3. Biochem Pharmacol 74:161–8.
   PubMed Web of Science ®Google Scholar
• Wolff NA, Burckhardt BC, Burckhardt G, et al. (2007). Mycophenolic acid (MPA) and its glucuronide metabolites interact with transport systems responsible for excretion of organic anions in the basolateral membrane of the human kidney. Nephrol Dial Transplant 22:2497–503.
   PubMed Web of Science ®Google Scholar